SELANK Research:
Anxiolytic Peptide & Cognitive Benefits
SELANK is a synthetic heptapeptide anxiolytic developed from the endogenous neuropeptide tuftsin. It has been researched for its anxiolytic, nootropic, and immunomodulatory properties, with a particular profile of interest in behavioral neuroscience models.
What Is SELANK?
SELANK (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It was designed by extending the structure of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide, with the Pro-Gly-Pro sequence to improve metabolic stability and central nervous system penetration.
SELANK has been registered as an anxiolytic drug in Russia (Selank nasal spray) and has been extensively studied in preclinical rodent models and some human trials for anxiety, cognitive enhancement, and immunomodulation. Its research profile distinguishes it from classical benzodiazepines through a proposed absence of tolerance, dependence, or cognitive impairment. Lumen Peppers supplies research-grade SELANK for laboratory investigation.
Key Research Findings
Anxiolytic Activity
Rodent elevated plus-maze, open field, and conflict tests consistently show SELANK reduces anxiety-like behavior with efficacy comparable to diazepam, but without observed sedation or motor impairment in most studies.
Cognitive Enhancement
Spatial memory tests (Morris water maze, radial arm maze) and attention models show SELANK improves learning acquisition and memory consolidation in rodents — effects attributed to BDNF upregulation and enhanced synaptic plasticity.
BDNF & NGF Upregulation
Gene expression studies show SELANK significantly increases BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor) mRNA in hippocampal and cortical tissue, providing a proposed molecular basis for observed nootropic effects.
Immunomodulation
SELANK modulates cytokine expression patterns in rodent models — consistent with its tuftsin-derived immunostimulatory base. Studies show effects on IL-6, IFN-γ, and enkephalin expression, though the net immune effect is context-dependent.
Stress & HPA Axis
Models of chronic stress show SELANK attenuates corticosterone elevation and prevents stress-induced immune suppression in rodents. The HPA axis-normalizing effect distinguishes it from compounds that directly block glucocorticoid signaling.
Neuropeptide Degradation
SELANK inhibits degradation of Met-enkephalin by inhibiting enkephalinases in rodent brain tissue extracts. This enkephalin-sparing effect may contribute to both anxiolytic and analgesic aspects of its preclinical profile.
Proposed Mechanisms of Action
SELANK potentiates GABA-A receptor activity in rodent CNS models, increasing chloride conductance in hippocampal neurons. Unlike benzodiazepines, it appears to modulate the receptor without direct binding at the BZ site, potentially explaining its lack of tolerance development in research models.
SELANK markedly upregulates BDNF gene expression in rat hippocampal and cortical tissue within hours of administration. BDNF signals through TrkB receptors to activate MAPK/ERK and PI3K/Akt pathways — core mechanisms for synaptic potentiation and memory consolidation.
SELANK competitively inhibits the enzymes responsible for Met-enkephalin degradation (neprilysin, ACE), increasing endogenous opioid tone in CNS tissue. This is proposed to contribute to its anxiolytic and mood-modulating effects.
Rodent microdialysis studies show SELANK modulates serotonergic neurotransmission in the frontal cortex and increases dopamine release in the striatum — neurochemical changes consistent with its anxiolytic and pro-cognitive effects.
SELANK attenuates stress-induced corticosterone elevation in rodents without blocking glucocorticoid receptors directly. This normalization of HPA axis activity may explain both anxiolytic effects and stress-induced immune preservation.
Active Research Applications
Anxiety Models
Elevated plus-maze, open field, and light/dark box tests in rodents examining SELANK's anxiolytic profile vs. benzodiazepine and SSRI reference compounds.
Cognitive Research
Spatial and contextual memory assays in rodents examining SELANK effects on learning acquisition, memory consolidation, and retrieval — with BDNF as a proposed biomarker.
Neurotrophic Biology
In vitro neuron culture studies examining SELANK-induced BDNF, NGF, and NT-3 expression; dendritic arborization; and synaptic protein expression.
Stress Physiology
Chronic unpredictable stress models measuring HPA axis normalization, corticosterone levels, and immune cell function preservation with SELANK treatment.
Neuroimmunology
Models examining SELANK's dual role in CNS and peripheral immune systems — cytokine modulation, NK cell activity, and T-cell function studies.
Pharmacology Studies
Dose-response, bioavailability, and CNS penetration studies — including intranasal vs. subcutaneous route comparisons and metabolite identification.
SELANK vs. SEMAX
Both SELANK and SEMAX are neuropeptides derived from endogenous peptides with related but distinct research profiles.
SELANK
SEMAX
Protocol Notes for Researchers
SELANK — Research Grade ≥99% Purity
Research-grade purity ≥99% · Third-party HPLC verified · Ships from the U.S.
All products sold by Lumen Peppers are intended exclusively for in vitro laboratory research and investigative purposes. These compounds are not approved by the FDA for human or veterinary use. They are not drugs, supplements, or medications. Lumen Peppers makes no therapeutic claims. Researchers are solely responsible for ensuring compliance with all applicable laws and regulations in their jurisdiction.